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1.INTRODUCTION 
 
The diagnosis of Fatty liver is often, an uninvited one. Many a times the 
diagnosis of Fatty liver is made when the patient is undergoing radiological 
investigations like USG or CT scan of the abdomen for an unrelated purpose. And 
clinicians are seeing more and more cases of radiologically diagnosed, incidentally 
detected fatty liver disease. Increasing use of radiological diagnostic modalities, 
health checkups and screening programs and more over the epidemic of obesity 
and metabolic syndrome contribute to this phenomenon.  
Fatty liver is a clinico - histopathologic entity. In simple terms it refers to the 
accumulation of fat (triglyceride vacuoles) in hepatocytes. Fatty liver disease can 
range from steatosis to steatohepatitis. This condition can occur with the use of 
alcohol (alcohol-related fatty liver) or in the absence of significant alcohol 
consumption (nonalcoholic fatty liver disease also known as NAFLD) 
This study is an attempt to find more about such radiologically detected 
fatty liver disease in totally asymptomatic and otherwise healthy individuals. A 
diagnosis of Fatty liver is of no less significance, even when the patient is 
asymptomatic and appears totally healthy. It may be the first warning of a 
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potentially dangerous metabolic abnormality, toxic effect of alcohol abuse, drugs 
or some rare liver disorders. This finding warrants a detailed clinical and 
laboratory evaluation and targeted therapies.   
Stanley Medical College caters to a large population of people in and 
around north Chennai. And the physicians here do come across a good number of 
radiologically diagnosed fatty liver disease. Moreover studies from the city have 
shown that there is a disproportionate prevalence of patients with metabolic 
abnormalities that results in high cardiovascular risk. 
By this study a profile of such asymptomatic incidentally detected fatty 
liver patients is looked into. The proportion of alcohol and non alcohol related fatty 
liver disease is analysed. An effort is made to study the various clinical and 
biochemical abnormalities, its proportion, and association with metabolic 
syndrome. By this study a possible algorithm to approach such a case can be made 
out which is relevant to the study population (i.e., Northern Chennai). And in the 
next step high sensitive C reactive protein levels are being evaluated. Being a pro-
inflammatory marker and an in depended cardiovascular risk factor, hsCRP may 
provide a clue regarding the cardiovascular risk status of such cases and also the 
potential link between all the metabolic abnormalities. 
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2.AIM OF THE STUDY 
 
1. To assess the Clinical profile of asymptomatic cases diagnosed with Fatty 
liver by routine radiological screening methods like USG and CT Abdomen. 
2. To study the laboratory pattern associated with alcoholic and non alcoholic 
causes of fatty liver disease.  
3. To find out the proportion of alcoholic and non alcoholic fatty liver disease. 
4. To obtain an idea about the prevalent and strongly associated metabolic 
anomaly associated with fatty liver disease. 
5. To study the prevalence of Metabolic Syndrome in the group. 
6. Assessment of serum levels of high sensitivity C - Reactive Protein, a 
marker of proinflammatory state and independent CAD risk factor in cases 
diagnosed with Fatty liver disease. 
7. Evaluation of hsCRP levels with respect to the various clinical and 
biochemical abnormalities and find the correlation. 
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 3.REVIEW OF LITERATURE 
 
  Fatty liver once a histopathological term used to denote fat accumulation 
in the liver now has become a clinical diagnosis based on imaging and biopsy. 
Microscopic examination a fatty liver is charactersied by inytracytoplasmic 
accumulation of triglycerides.1 On ultrasound imaging the fatty liver produces a 
diffuse and non specific increase in echogenicity, which usually is compared with 
the kidneys.2 Fatty liver disease is a common clinical condition which is fast 
assuming importance as a possible precursor of more serious liver disorders, 
including cirrhosis of the liver and hepatocellular carcinoma. 
Classification 
Fatty liver is classified mainly into Alcohol related and Non alcoholic Fatty 
liver disease.3 The vast majority of cases in the Non alcoholic fatty liver group 
consist of patients with obesity, insulin resistance, hypertension and various lipid 
abnormalities.4 And over the last few decades, the term Non alcoholic fatty liver 
disease became the representative term for such a disease profile. Nevertheless, 
non alcohol etiology can be many. Fatty liver, according to the recent literature is 
classified into the following. 5 
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• Fatty Liver Disease related to alcohol etiology 
• Non Alcoholic Fatty liver Disease (NAFLD) 
(1) Drugs and toxins   
(2) Metabolic abnormalities, either acquired or congenital 
(3) Surgical Procedures 
(4) Inborn Errors of Metabolism 
 
Figure 3.1 Classification of Fatty liver 
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           Table 3.1 Miscellaneous causes of fatty liver 
 
Acquired Metabolic Disorders 
 
Congenital Metabolic Disorders 
 
Obesity 
Diabetes mellitus 
Hyperlipidemias 
Kwashiorkor and marasmus 
Starvation 
 
 
 Familial hepatosteatosis 
 
 Galactosemia 
 
 Glycogen storage disease 
 
 Hereditary fructose intolerance 
 
 Homocystinuria 
 
 Systemic carnitine deficiency 
 
 Tyrosinemia 
 
 Weber-Christian syndrome 
 
 Wilson disease 
Abetalipoprotenemia 
 
 
Drugs and Toxins 
 
 
Surgical Conditions 
 
 
Cytotoxic Drugs 
Estrogen 
Chromates 
Barium salts 
Glucocorticoids 
Others 
Valproic acid 
 
 
 Extensive small bowel resection 
 
 Gastric bypass 
 
 Jejunoileal bypass 
Biliopancreatic diversion 
Severe Anemia 
TPN 
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The vast majority of fatty liver disease which present without alcohol 
etiology has a particular pattern. It is spectrum often compared with metabolic 
syndrome, a spectrum of obesity, insulin resistance, dyslipidemias and 
hypertension. The original intention and the literary meaning of NAFLD – Non 
alcoholic fatty liver disease was to include all causes of fatty liver other than 
alcohol. However since the most cases of non alcoholic fatty liver now represents 
the metabolic syndrome pattern, the term NAFLD has eventually became a 
representative of that group. 
 
Non Alcoholic Fatty Liver Disease 
Non alcoholic fatty liver disease is a common cause of chronic liver disease 
and its incidence is rising worldwide.  Ever since Ludwing, Jurgen etal from Mayo 
clinic 7 described the histological finding in fatty liver and coined the term “Non 
alcoholic steatohepatitis (NASH)”, this terminology been studied, researched and 
published a lot, especially in the last decade. Non alcoholic fatty liver disease is 
now considered a spectrum of liver disease which can be benign (simple steatosis) 
or one which can inflict serious damage to liver and result in cirrhosis and  
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complications (steatohepatitis). Nonalcoholic fatty liver disease (NAFLD), 
encompasses simple fatty liver, NASH, and NAFLD-associated cirrhosis.  
 
Defining Fatty Liver 
 
 
Fatty liver can be defined by the presence of at least two of three abnormal 
findings on abdominal ultrasonography: diffusely increased echogenicity (‘bright') 
liver with liver echogenicity greater than kidney or spleen, vascular blurring, and 
deep attenuation of ultrasound signal. 8 NAFLD is highly likely provided that the 
other causes of liver disease have been rigorously excluded, particularly significant 
alcohol intake (more than 140 g weekly in men, 70 g weekly in women) and 
medication use. In patients with otherwise unexplained ALT elevation, NAFLD is 
highly likely to be the cause if hepatic imaging results are compatible with fatty 
liver, and metabolic risk factors are present. Serum ALT elevation secondary to 
other causes and preexisting liver diseases has to be ruled out. 
 
NASH, a subset of NAFLD is the term used to describe the clinical entity 
in which patients lacking history of significant alcohol consumption but have liver 
biopsy finding similar to alcoholic steatohepatitis. 9 
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Epidemiology 
NAFLD was considered to be a disease prevalent in western and industrialized 
countries. However there is a considerable increase in prevalence rate detected 
from developed countries. 10,11,12  Studies report a prevalence of 20 to 40 percent in 
western population and 5 to 30 percent in Asia Pacific Population. 11, 13, 14 
Although in the general population, the prevalence of NAFLD and NASH 
are approximately 20% and 3% respectively, in obese population, NAFLD may 
even go up to 75% of the subjects. 
Indeed, in morbidly obese, steatosis (NAFLD) has been found in almost all 
subjects, with NASH being present in 25%-70% of these individuals. It has been 
estimated that approx 70-75% of type 2 diabetic subjects may have NAFLD.  
However, these studies were mainly done in western populations. South Asians in 
general and Asian Indians in particular, have very high rate of diabetes, insulin 
resistance and premature CAD. 17  
Given below is a table of comparison of NAFLD prevalence in Asia, 
compiled from different studies 10-17 
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Table 3.2 : Prevalence of NAFLD among Adult Population of Asia-
Pacific Countries. 
Country Individuals with NAFLD (%) 
Japan 9-30 
China 5-24 
Korea ~18 
India 5-28 
Indonesia ~30 
Malaysia 17 
Singapore 5 
 
NAFLD IN INDIA 
Overall prevalence of NAFLD is around 10-20% based on the data on 
people undergoing master health check up, ultrasongography for non-liver related 
causes, healthy relatives of hospitalized patients, and railway employees and their 
families. The epidemiological studies that have been carried out in various parts of 
India to find out the prevalence of NAFLD of studies using histological criterion to 
diagnose NAFLD, shows varying results.  
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Table 3.3 -Aggregated region wise prevalence of NAFLD in India, from 
various studies. 10,14,18 
 
Region n Male : Female Prevalence Study 
West 210 2:1 55.4 ± 9 Amarapukar et 
al. , 2000 
East 63 2:1 42.7 Singh et al., 
2004 
West 730 1:1 39.08 ± 12.3 Amarapukar et 
al., 2007 
West 225 3:1 30± 12 Uchil et al., 2009 
North 100 2:1 37.8±10.7 Duseja et al., 
2006 
North 150 3:1 42.2±10.5 Bhat et al., 2006 
North 25 4:1 33 Agarwal et al., 
2001 
 
Pathogenesis 
Much has been learned regarding the pathogenesis of fatty liver in the last 
decade, till the complete pathogenesis has not been understood to the full extend. 
Both insulin resistance and retention of lipids within the hepatocytes are mostly 
implicated in pathogenesis of NAFLD. A second hit theory which is essentially a 
oxidative injury mechanism has also been suggested. 19 
Strong epidemiological, biochemical, and therapeutic evidence support the 
premise that the primary pathophysiological derangement, in most patients with 
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NAFLD, is insulin resistance. Insulin resistance leads to increased lipolysis, 
triglyceride synthesis, increased hepatic uptake of free fatty acids, and 
accumulation of hepatic triglyceride. Several fat derived hormones, such as 
adiponectin, leptin, and resistin, are important regulators of hepatic insulin 
sensitivity. At the cellular level, these effects appear to be modulated through 
altered activation of numerous receptors, membrane glycoproteins, and cytokines. 
Factors that determine the presence and extent of necroinflammation are not yet 
well understood.20Sseveral possible mechanisms have been theorized, including 
host factors, such as defects in mitochondrial structure and function, impaired free 
oxygen radical scavengeing, increased hepatic iron, and hepatotoxic byproducts of 
intestinal bacteria.21 Activation of both lobular stellate cells and hepatic progenitor 
cells have been observed in NAFLD. 20, 21, 22,23 
Clinical Features and Natural course of the disease 
Majority of NAFLD cases are diagnosed radiologically during health 
screening or unrelated issues. Few cases are diagnosed while evaluations are being 
undertaken for altered liver function tests. So a vast majority of the patients can be 
asymptomatic.  If present, the commonest symptoms include fatigue, malaise and 
right upper quadrant discomfort, and mild jaundice. Hepatomegaly is also a 
frequent finding on clinical examination. It has been reported upto 75% of patients, 
but these findings do vary a lot. 24 
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Table: 3.4 Primary Presentation of 100 Consecutive cases of 
Incidentally Detected NAFLD. 24 25 
Primary Representation Number of Patients 
Non-ulcer Dyspepsia 43 
Irritable bowel syndrome 29 
GERD 7 
Peptic ulcer 6 
Intestinal tuberculosis 3 
Functional abdominal pain 3 
No symptoms (asymptomatic 
spouses of NAFLD patients) 
2 
Biliary colic 1 
Elevated transaminase 3 
HBV carrier 3 
The natural history of NAFLD is quiet variable. A predicted evolution based on the 
current data is decapitated on figure given below.  
Figure 3.2 Natural History of NAFLD 
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A population based study showed only a slightly lower survival rates than 
general population.26 Increasing age, Glucose intolerance and existence of cirrhosis 
were associated with increased mortality.   
In patients with simple steatosis, progression to cirrhosis may occur in 4%-
5% over a period of 8-15 years, while steatohepatitis progress in over 25% patients 
over the same period.27 At initial biopsy 5-25% of patients with NAFLD may have 
cirrhosis. Once cirrhosis develops the cumulative probability of complications and 
need for transplantation and mortality is same as hepatitis C related cirrhosis.28 
Pathology 
The major histological features of NAFLD resemble those of alcohol-induced liver 
disease and include steatosis, steatohepatitis (parenchymal inflammation with or 
without accompanying focal necrosis), and varying degrees of fibrosis, including 
cirrhosis. 30 Steatosis is predominantly macrovesicular and usually is distributed 
diffusely throughout the liver lobule, although prominent microvesicular steatosis 
and zone 3 (perivenular) steatosis have been reported occasionally.  Mild 
lymphocytic, neutrophilic, or mixed inflammatory infiltrates also may be observed, 
and glycogenated nuclei are common. NASH, which is an advanced form of 
NAFLD, is indistinguishable histologically from alcoholic hepatitis. 31 Steatosis is 
present in all cases and can affect the hepatic lobules either diffusely or primarily 
in the central zones. The intensity of the inflammation varies with the severity of 
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steatohepatitis and may be milder in NASH than in alcoholic hepatitis. 31 
Glycogenated nuclei may be present. Hepatocyte ballooning and hepatocyte 
necrosis of varying degrees often are present and may portend a worse prognosis. 
[32, 33]
 Mallory (or Mallory-Denk) bodies, which may be small, sparse, and 
inconspicuous, are seen frequently. Mild stainable iron may be present in up to 
50% of the patients.  Pericellular, perisinusoidal, and periportal fibrosis has been 
described in 37% to 84% of patients with NASH. The extent of fibrosis varies 
considerably, ranging from delicate strands surrounding small veins or groups of 
cells to densely fibrotic septa with distortion of the hepatic architecture 32The 
Pathology Committee of the NASH Clinical Research Network and several other 
bodies have designed and validated a histological feature scoring system that 
addresses the full spectrum of lesions of NAFLD and proposed a NAFLD activity 
score (NAS) for use in clinical trials 33 34                                                     
Table 3.5 Scoring system for NASH 
Necro-inflammatory Grading 
Grade 1 (Mild) Steatosis (mainly 
macrovesicular) involving up to 66% 
of lobules; occasional ballooned 
perivenular hepatocytes; scattered 
neutrophils; with or without 
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lymphocytes; no or mild chronic portal 
inflammation. 
Grade 2 (Moderate) Steatosis of any degree; 
obvious ballooning; intralobular 
neutrophilis; perivenular pericellular 
fibrosis; mild to moderate portal and 
intralobular chronic inflammation. 
Grade 3 (Severe) Panlobular steatosis; prominent 
ballooning and disarray; marked 
lobular inflammation, neutrophil and 
lymphocyte pattern similar to grade 2. 
Fibrosis Staging 
Stage 1 Pericellular fibrosis, 
perivenular areas. Focal or extensive 
Stage 2 As above, plus focal or 
extensive periportal fibrosis 
Stage 3 Bridging fibrosis, focal or 
extensive 
Stage 4 Cirrhosis 
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Metabolic Syndrome and Fatty Liver 
The term metabolic syndrome refers to a constellation of the risk factors if 
present together have been reported to increase the risk of cardiovascular disease. 
The most common accepted definitions of MS as of today are those set out by the 
International Diabetes Federation, the WHO, and the National Cholesterol 
Education Program – Adult Treatment Panel – III (ATP III) recommendation. The 
ATP III recommendations are detailed in Table 3.629 
The main pathophysiological mechanisms in metabolic syndrome are 
insulin resistance and obesity. Various guidelines are formed in view of the above 
factors. Treatment history for hypertension, diabetes or dyslipidemia is a also taken 
into consideration even when the investigatory parameters and clinical examination 
is normal. 
The pathophysiological mechanism – insulin resistance and excess 
circulating free fatty acids are both common to metabolic syndrome and fatty liver. 
Some authorities have termed fatty liver as the “hepatic component of Metabolic 
syndrome” 36 The risk factors for the development of NASH were identified as 
those related to metabolic disorders, obesity, type 2 diabetes mellitus (T2DM), and 
dyslipidemia. By the late 1990s, NASH was conceptualized as part of the 
metabolic syndrome.  
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Table 3.6 Definition of Metabolic Syndrome according to Modifiied 
ATP –III criteria (2004) 
 
Risk Factors Modified ATP –III criteria (2004) 
Obesity (BMI) Not used for diagnosis 
Abdominal obesity Waist circumference M: ≥ 90cm, F: ≥80cm * for Asian 
population 
Blood Pressure Systolic: ≥ 130 and/or Diastolic: ≥ 85 mmHg or on 
medication 
Fasting plasma glucose ≥ 100mg/dL (6.1 mmol/L) or on medication for diabetes 
Micro-albuminuria Not used for diagnosis 
Triglycerides ≥ 150 mg/dL (1.7 mmol/L) 
HDL Cholesterol M: <40mg/dL (1.04 mmol/L), F: <50 mg/dL (1.3 mmol/L) 
Metabolic syndrome 
definition 
At least any three risk factors 
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Though it looks theoretically attractive to call NAFLD as hepatic 
component of metabolic syndrome, a lot need to understand regarding fatty liver 
pathogenesis and physiology before this is being put into practice.37, 38 
Diagnosis - 
Labortary Studies. 41 42 
Mild to moderate elevation of AST and ALT can be present in cases of 
NAFLD and more so in cases of NASH. The AST/ALT ratio is generally less than 
one. The AST and ALT values can be anywhere between 1.5 to 4 times the upper 
limit of normal. Very high (x10times or more) elevation of AST and ALT should 
raise the suspicion of alternate diagnosis. The serum ALT level usually is greater 
than the AST level, in contrast with the pattern of alcoholic hepatitis, in which the 
AST level is at least twofold higher than the ALT level. The serum levels of 
alkaline phosphatase may be also elevated in cases of NAFLD. But other liver 
function values tend to be normal unless there is associated cirrhosis or hepatic 
dysfunction. 36 Some patients, in some studies upto 25% of NAFLD population 
was associated with low positive titers of ANA (Anti nuclear antibodies) Increased 
Ferritin levels, elevated transferrin saturation, autoantibodies, hypoalbubinemia, 
prolonged prothrombin time etc can be associated with NAFLD. Viral serology, 
mostly for Hepatits B and C infections, serum Alfa protein levels and 
ceruloplasmin levels should also be measured as a part of evaluation 39,40 
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Imaging 
Ultrasound is the most commonly used modality for detection of hepatic 
steatosis. On USG fatty liver is seen as a bright liver with echogenicity of liver 
more than right kidney. Overall USG has a sensitivity of 60%-90% and specificity 
of 84%-95% for detecting fat, but combined fat and fibrosis can show hyper echoic 
lesion in liver up to 98.7% of patients, known as fibrofatty pattern . The USG 
pattern can be focal or diffuse. Diffuse steatosis may be of three types 41 
1. Mild: Minimal diffuse increase in hepatic echogenicity, normal 
visualization of diaphragm and intrahepatic vessel borders. 
2. Moderate : Moderate increase in hepatic echogenicity , slightly 
impaired visualisation of intrhepatic vessels and diaphragm 
3. Severe : marked increase in echogenicity, poor penetration of 
the posterior segment of right lobe of love and poor or non visualization of 
the hepatic vessels and diaphragm 
Contrast ultrasound has been used to pick up fibrosis and differentiate 
patients of NASH and NAFLD. Focal fat may show rapid change with time both in 
appearance and resolution, it does not alter the course or caliber of regional blood 
vessels and does not produce contour abnormalities. Sometimes focal  fat may 
produce geographic map-like boundaries. 
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CT Scan Normal attenuation of liver is between 50 and 75 HU and is more than 
the spleen by 4-8 HU. As liver gets fatty its attenuation decreases and may become 
less than that of the spleen with a difference up to 10HU or less. Liver attenuation 
decreases by 1.6HU/mg of Triglyceride deposited per gram of liver tissue. In 
patients with severe steatosis attenuation of liver is less than blood in portal and 
hepatic veins. Data from the transplant donors have shown that non contrast CT is 
helpful in detecting steatosis of 330% or more with 100% specificity and 82% 
sensitivity. CECT can be used to quantify the amount and degree of steatosis. 42 
MRI – Magnetic resonance imaging is the most accurate non invasive modalities 
available technique for detection and quantification of hepatic steatosis. Chemical 
Shift MRI and MR Spectroscopy offers added advantage fatty liver imaging in 
terms of better sensitivity and with its ability to delineate steatosis and fibrosis  
Fibroscan - Fibroscan is based on one dimensional elstography and used both 
USG and low frequency elastic (50) HZ waves to measure the liver stiffness. It has 
the ability to detect fibrosis in addition to fatty liver. 
Liver Biopsy - Liver biopsy is the gold standard for diagnosis of NASH and 
fibrosis. Liver biopsy is the only diagnostic test that can reliably quantify hepatic 
steatosis, necrosis, and fibrosis; and the histologic stage of NAFLD and biopsy 
finding is the best prognostic indicator. But being an invasive procedure the role of 
liver biopsy in establishing the diagnosis of NAFLD has been debated. Potential 
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complications, limited therapeutic options even after diagnosis, the cost and time 
consumed etc make liver biopsy a less favored option among clinicians. However 
selected cases do warrant histopathological examination. The correlation among 
clinical, laboratory, and histologic findings in NAFLD is poor, and patients with 
normal liver biochemical test results can have significant liver injury on biopsy 
specimens; So in case of doubt or doubtful diagnosis, in cases assessing the 
prognosis is important, liver biopsy may be the answer. 47 
Non Invasive Methods 43 
Although percutaneous liver biopsy remains the gold standard for the diagnosis of 
NAFLD, the procedure is costly, time consuming and with some complications. 
The more and more cases being diagnosed as fatty liver and the search for non 
invasive methods has led to the development of non invasive methods to asses fatty 
liver and fibrosis.  
Using varying combinations of indirect markers scoring systems have been 
developed and evaluated to estimate the extent of liver fibrosis and its aggravating 
factors in steatosis, and NASH, These tests include FibroTest, and NashTest, 
FibroMax (Biopredicive, Paris France).  
The Fibro Test also called FibroSure in some countries, is the most studied 
and anlaysed among the above said noninvasive tests. The panel of blood tests 
used to estimate hepatic fibrosis includes serum α2-macroglobulin, apolipoprotein 
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A-1, haptoglobin, total bilirubin, and GGTP levels, and the necroinflammatory 
activity index combines the same five markers plus the serum ALT level.  In a 
study of 167 patients with NAFLD, FibroTest was highly sensitive for detecting 
bridging fibrosis and cirrhosis. FibroTest cutoff value of .70 had a positive 
predictive value of 73% and a specificity of 98% for advanced fibrosis. A cutoff 
value of 0.30 had a negative predictive value of 90% for advanced fibrosis. 
Unfortunately, 33% of patients had a FibroTest score between 0.30 and 0.70, and 
in this range, the test is inaccurate for assessing the stage of fibrosis. Therefore, 
patients with a score in this range would need a liver biopsy for accurate staging. It 
must be emphasized that hepatic fibrogenesis is a dynamic process, and most of the 
tests available are more relevant for determining the rate of fibrosis progression or 
response to treatment than to assess fibrosis at a particular point in time. One or 
more noninvasive indices of fibrosis is likely to be validated in the future and may 
supplant the need for liver biopsy in many, but not for all patients with 
NAFLD.44,45 
Assessment of NAFLD 29 
 Careful history: particularly history of alcohol consumption 
 Anthropometry: to find out the height, weight, BMI and waist circumference  
 Blood pressure measurement 
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 Biochemical tests: serum bilirubin, serum AST, ALT, Gamma GT, albumin, 
globulin, fasting sugar, fasting lipid profile. 
 Hematological tests: complete blood count, platelet count 
 Serological and immunological tests: Anti-HCV, HBsAg, Hepatitis B core 
antibody. ANA, ASMA, Anti-LKM, AMA as clinically indicated 
 Metabolic tests: serum ceruloplasmin, serum ferritin as clinically indicated 
 Insulin sensitivity: fasting blood glucose, serum insulin fasting 
 Abdominal ultrasound: with particular reference to liver echogenicity and its 
comparison with echogenicity of kidney and spleen vascular blurring and 
deep attenuation of ultrasound signal.  
 Optional tests: abdominal CT scan, liver biopsy, biomarkers for liver fibrosis 
Treatment of NAFLD 
There is no single therapy for NAFLD. The treatment includes a multitude 
of approaches targeting the pathophysiological mechanisms 51 
 The metabolic associations like diabetes, dyslipidemia , obesity and 
hypertension 
 Improving insulin resistance by weight loss, exercise or pharmacotherapy 
 Hepatoprotective agents such as antioxidants to protect the liver from 
secondary insults 
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Lifestyle changes are the proven, mainstay and cost effective interventions 
target at NAFLD. But adherence and motivation to continue the changes lifelong 
remains an issue. Studies have shown that moderate amount of weight loss and 
exercises are associated with improvement in insulin sensitivity. A targeted weight 
loss of 7-10% of the baseline weight reduction in 6-12 months should be the initial 
goal. The weight loss should be achieved gradual and sustained manner. 52 
The optimal die to treat NAFLD is not known, however patients with 
NAFLD seem more likely to have a diet high in saturated fats and cholesterol and 
low in fiber and antioxidants. Mono and poly unsaturated fats may potentially 
improve insulin resistance and may be beneficial in improving hepatic steatosis. 
Associated metabolic abnormalities have to be treated according to 
guidelines. A definitive improvement in the liver histology and a reduction in 
cardiovascular mortality can be expected if diabetes, hypertension and dylipidemia 
are adequately treated and well controlled. Among the anti obesity drugs, orlistat 
shows some promise. A small pilot study by Harrison et al showed improvement in 
aminotransferases with a mean 10kg reduction weight after a treatment with 
Orlistat for 6 months. 
As insulin resistance is a key factor in pathogenesis of NAFLD people have 
used insulin sensitizers for the treatment of NAFLD. Biguanides and 
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thiozolidinediones are the two class of insulin sensitizers studied in human with 
proven results. Liver histology also shows improvement after treatment. 
Hepatoprotective agents and antioxidants being studied include  VitaminE, 
Urosodeoxycholic acid (UDCA), pentoxyphylline, betaine, probucol, silymarin and 
iron depletion agents. Most of the studies are in Phase 2 or 3 clinical trials and 
outcomes are awaited. 53 
                     
Alcohol Related Fatty liver 
 
 Alcoholic fatty liver is an early and reversible consequence of excessive 
alcohol consumption.  Alcoholic fatty liver (steatosis) is rarely diagnosed clinically 
because most patients are not symptomatic and usually do no seek medical 
attention. However, up to 90 percent of alcoholics have steatosis. Reports are 
available describing the development of fatty liver even with hours of alcohol 
binge. Fatty liver, in general represents the direct toxic effects of ethanol, in 
alcoholics. Population derived studies have documented  in the literature that men 
usually must drink 40g to 80 g of alcohol daily and women 20g to 40 g daily for an 
average of 10 years to achieve a significant risk of liver disease. And duration 
shorter than this can cause fatty liver changes rather than full blown cirrhosis. 54 
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Alcoholic fatty liver may be suspected in patients with a compatible history 
who have a suggestion of fatty liver on imaging tests or are found to have steatosis 
on liver biopsy. Liver tests are generally normal or modestly elevated, and jaundice 
is unusual. The diagnosis is established after excluding other causes of fatty liver. 
The progression of liver damage is shown in the following figure.3.3 But it 
might be taken into account that, individual variation do occur considerably. 
 
Figure 3.3 Progression in Alcoholic liver disease 54 
 
Chronic alcohol abuse can result in a spectrum of liver injury that ranges 
from mild fatty infiltration to cirrhosis and hepatocellular carcinoma. Fat 
accumulation in liver cells, which is the earliest and most predictable response to 
alcohol ingestion, is seen in 90% of heavy drinkers. Although fatty liver generally 
is a benign condition that usually reverses quickly with abstinence, cirrhosis can 
develop within five years in 10% of patients who continue to drink heavily.55 
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The histological picture is almost similar are described earlier for NFLD. 
Characteristic features include liver necrosis, mallory bodies, Infiltration by 
neutrophils , perivenular distribution of inflammation etc. Other nonessential 
histologic features include bridging necrosis, fatty changes, bile duct proliferation, 
cholestasis, and perivenular fibrosis. The presence of neutrophils is a hallmark of 
alcoholic hepatitis. 34,35 
In short fatty changes in a chronic alcoholic suggest that the process is of a 
shorter duration than needed for cirrhosis. The hallmark of this stage is that it is 
reversible, and it provides a potential opportunity to prevent cirrhosis and 
malignant transformation in future 
 
High Sensitivity C - reactive protein 
 
CRP is an acute phase reactant secreted by hepatocytes under the influence 
of acute inflammatory cytokines such as IL-1,IL-6 and  TNF.  Inflammatory 
markers can be used as a guideline for detecting underlying atherogenesis as well 
for recurrence in underlying atherogenesis. 56 
Whether CRP is just a causal component of the atherosclerotic process or a 
factor involved in the process is an unsolved question. Evidence is mounting that it 
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is not causal. The following observations are strongly in favor that CRP may have 
a direct role in the atherosclerotic disease causation and progression 57 
 CRP has been detected in atherosclerotic lesions.  
 CRP binds to LDL, allowing LDL to be taken up by macrophages 
without the need for modification  
 Recombinant human CRP was infused into seven normal men in 
whom very high serum CRP concentrations were attained (mean 
23.9 mg/L). The CRP infusion was associated with marked 
elevations in markers of both inflammation (IL-6, IL-8, and serum 
amyloid A) and coagulation (von Willebrand factor antigen, 
prothrombin F1±2, D-dimer, and plasminogen activator inhibitor 
type 1). 
 In an animal model of increased atherosclerosis, treatment with 
native CRP increased aortic plaque area. 
 CRP induces adhesion molecule expression and the production of 
interleukin-6 and monocyte chemoattractant protein-1 (MCP-1) in 
human endothelial cells; these effects might enhance a local 
inflammatory response within the atherosclerotic plaque by the 
recruitment of monocytes and lymphocytes. 
Rat models of myocardial infarction have shown in a study conducted by 
johnson etal in 2007 that CRP inhibitors would decrease the infarct size  and that 
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effect could be blocked by a synthetic small molecule inhibitor of CRP. CRP 
induced complement activation is one of the central pathogenesis pathway of 
myocardial infarction and thus inhibitors binding to CRP blocking this effect has a 
use beyond doubt. In a stable coronary artery disease patient CRP levels correlate 
mostly with the risk of plaque rupture and the extent of underlying atherogenesis. 
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CRP as a predictor of progression of CAD has attracted worldwide 
attention. In a study conducted in Belgium in 2009 it was found out that elevated 
CRP levels were associated with inducible ischemic changes on stress testing. This 
study threw light on the fact that CRP levels could be used as a tool in angina 
patients who were at risk for ACS in the future. It was found that CRP, SAA, IL-6 
were indicative of the hyper responsiveness of the inflammatory system to small 
amount of stimulus thus underlying its importance. CRP at a higher level was 
associated with increased plaque vulnerability and more strongly associated with 
STEMI than NSTEMI. CRP has also been proven to be an indicator of recurrent 
ischemia risk after CABG. Elevated pre procedural levels are associated with poor 
outcome. 
In the famous VAL HEFT TRIAL OF 2008 median levels of CRP were 
found to be higher in patients with heart failure when compared to normal 
population. CRP levels and sudden cardiac death however didn’t have any such 
direct association. 
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 CRP was also a predictor of transplant coagulopathy and allograft failure 
in post cardiac transplant patients. An inflammatory process may trigger AF in 
patients post cardiac transplant and hence CRP could be a useful marker. 
In the famous Women’s health study in USA conducted in 20,000 females 
it was proven that CRP is an independent predictor for the risk of developing 
hypertension in future. 
Traditional methods for measuring serum CRP were developed for use in 
patients with infectious and inflammatory disorders. These assays typically have a 
detection limit that in the range of 3 to 5 mg/L, which is above the concentration 
observed in most apparently healthy individuals. High sensitivity methods for 
measurement of CRP (hs-CRP) detect concentrations down to 0.3 mg/L. The 
assays are necessary for cardiovascular risk stratification, which is based upon 
discrimination of CRP levels extending below 3 mg/L. 59 
According to the centre for disease control and prevention and the 
American Heart Association   a value of <1, 1-3 and  >3 were given as low average 
and high values. A value of >10 should make us search for other markers of 
infection or inflammation and a value of >5mg/dl should be interpreted with 
caution. 58 
CRP levels in patients with Fatty liver are not studied extensively. 
Available studies have found increased level of CRP in these patients, and a 
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positive correlation to obesity, age, hypertension, and diabetes. Patients with 
steatoheaptitis have higher CRP levels than patients with steatosis alone. CRP is 
produced from liver and since the risk factors for CAD are often associations of 
fatty liver disease. More over increased CRP levels are reported in patients with 
metabolic syndrome and chronic liver disease. These factors suggest that a study of 
CRP levels in fatty liver disease can be of potential benefits in various ways.60 
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4.Material and Methods 
 
Inclusion Criteria 
Patients belonging to both sexes with age above 14 yrs who are otherwise 
asymptomatic detected to have Fatty liver in Ultrasonogram. 
 
 
Exclusion Criteria 
1. Symptomatic patients – Patients with short term or long term symptoms 
corresponding to any organ systems. 
2. Patients with any preexisting chronic illness or concurrent illness. 
3. Patients with any kind of drug intake. 
4. Known patients of Acute or Chronic Liver disease of any etiology. 
5. Patients with recent (<4wks) history of starvation or prolonged fasting. 
6. History of Gastro Intestinal Surgery or recent surgery (<3 months ) 
7. Patients with an hsCRP value of 5mg/L or more * 
*Since a value more than 5 mg/L denotes an acute inflammation, infection, trauma or surgery. 
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The study population was derived from patients and general public attending 
the Master Health Checkup of Stanley Medical College, Chennai from December 
2010 – November 2011 
               Fatty liver was diagnosed by Ultrasonogram, which was done by a 
Radiologist. All the images were reviewed by another radiologist to minimize 
observer error. The presence of fatty liver was graded from mild to severe. For all 
practical purpose it was taken present or absent. A Lasen &Toubro Ultrasound 
machine with a 3.5 MHz probe was used. 
 
After obtaining a written informed consent in the native language, a detailed 
inquiry was made into the history to rule out any clinical symptoms or significant 
past medical illness. History of surgeries in the past and medications were also 
enquired about. In addition women were enquired about oral contraceptives or 
hormonal use. History, duration and amount of alcohol consumption was also 
recorded. The presence or absence of alcohol intake was then independently 
confirmed by a family member of the patient. In selected cases psychiatric 
counselors help was obtained. 
After getting the history and relevant details, a thorough physical 
examination was done for the selected group. Vitals including pulse and blood 
pressure were recorded. Anthropometric measurements – weight, height, and waist 
circumference were measured. Waist circumference is measured with patient 
41 
 
stripped or when it’s not acceptable, with the patient wearing very light clothes. 
Adequate precautions were taken to minimize any potential errors. BMI is 
calculated as per the formula weight in kilograms divided by meter square. Patients 
were classified into 4 groups according to the calculated BMI 
Underweight: BMI <18.5 kg/m2 
Normal weight: BMI 18.5 to 24.9 kg/m2 
Overweight: BMI 25 to 29.9 kg/m2 
Obese : BMI > 30 kg/m2 
Blood sample was drawn for carrying the laboratory investigations. Laboratory 
investigations carried out includes Fasting blood sugar, after an overnight fasting 
of 8 hours, Liver function tests – Total bilurubin, AST, ALT and Alkaline 
Phosphatase, Lipid Profile which includes Total cholesterol, Triglycerides, HDL 
and LDL. Plasma hs-CRP level was measured by nephalometric method using the 
turbox-sf analyser. 
Standard Laboratory Normal Values: 
AST (Normal value 5 to 35 IU/L) 
ALT (Normal value 5 to 35 IU/L) 
Serum Alkaline Phosphatase (Normal 44 to 147 IU/L) 
Serum Total Bilirubin (Normal - < 1 mg/dl) 
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Research Design 
This is a cross sectional study assessing the clinical and laboratory profile of 
patients diagnosed with Fatty liver by radiology screening and assessing the serum 
levels of hsCRP 
 
Statistical Analysis 
Statistical analysis of the data obtained from the study was done using the ‘z’ test 
or ‘normal’ test to compare the mean values of two groups of participants.  Fishers 
exact test was also used when appropriate. The calculations were done for 5% level 
of significance (P = 0.05). Pearson product-moment correlation coefficient was 
used to find the correlation between hsCRP and other variables. Statistical analysis 
was carried out using Microsoft Excel ® and SSPS Software for predictive analysis 
from IBM ®. 
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5.RESULTS  AND  OBSERVATIONS 
 
In this study a total of 67 patients were included, after applying the exclusion 
criteria. Most of them presented to the Master Health Checkup Clinic and were 
found to have fatty liver during USG screening. 
There were 41 (61%) female and 26 (39%) male patients. 
 The mean ages of the participants were 48 ± 12.5 years. Majority of the patients, 
(40) belonged to 31 - 50 age group. 
Anthropometric characteristics 
The anthropometric characteristics measured include Weight, Height, and Waist 
circumference. Mean values obtained are given in the table below. P values were 
determined using student t test. 
       Table 5.1 Anthropometric characteristics of males and females 
 Male Female P value 
Weight (kg) 
 
72.23±12.36 67.4±13.25 0.14 
Waist Circumference 
(cm) 
 
85.73±11.58 83.7±12.61 0.51 
 
BMI (kg/m2) 
 
26.79±4.54 26.7±5.02 0.95 
 Figure 5.1 
Figure 5.2 
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The mean weight of male population was 72.2±12.4 kg and that for female 
population was 67.4±13.3. kg Waist circumference of male population was 
85.73±11.58 in cm and females 83.7±12.61 in cm. There was no statistical 
difference in any of the measured values between males and females.  
Waist Circumference  
Data regarding the waist circumference is given below. 17 males and 19 females 
had increased waist circumference, according to the ATP III criteria. 
 
Table 5.2 Waist Circumference Males and Females 
Waist 
circumference(males) 
Number Percentage (%) 
<90 cm 17 65.4 
>=90 cm 9 34.6 
 
Waist 
circumference(females) 
Number Percentage (%) 
<80 cm 19 46.3 
>=80 cm 22 53.7 
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BMI 
BMI is calculated from the weight and height as per the formula BMI = 
Weight in Kg/ (Height in meter)2. The population was then further classified into 
normal, overweight, obese class 1, class 2 and class 3 according to the BMI. The 
BMI value for males was 26.79±4.54 and for females was 26.7±5.02. The 
following table gives the results obtained. 
 
Table 5.3 BMI classes of the study population 
BMI (kg/m2) Male Female Total 
<18.5     Underweight 1 2 3  
18.5-25 Normal 10 16 26 
25-29.9    Over weight 9 12 21 
30-34.9  Obese - Class1 5 9 14 
35-39.9    Obese – Class 2 0 1 1 
>40        Obese – Class 3 1 1 2 
 
2 out of the 67 had morbid obesity. 26 patients had normal BMI characteristics. 21 
were overweight, 14 of them were having Class 1 obesity. 1 patient had class 2 
obesity. There were 3 patients, one male and 2 female who were having 
underweight according to the BMI class. 
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Figure 5.3 BMI wise distribution of the study population 
 
 
                   <18.5        18.5-24.9        25-29.9         30-34.9             35-39.9         >40 
 
  
0
5
10
15
20
25
30
BMI wise distribution
Male
Female
Total
48 
 
Clinical Characteristics 
There were 6 patients with clinically significant alcohol intake. This constitutes 
8.9% of the whole population. Enlarged liver was noted in 6 patients (8.9%). Viral 
serology for hepatitis – Hepatitis B and C were negative for all the 67 patients. 
 
Table 5.4 Clinical characteristics of the population 
Significant Alcohol Intake 6(8.9%) 
 
Hepatomegaly 
 
6(8.9%) 
Positive viral Marker 
HbsAg, anti HCV 
 
Nil 
 
Blood Pressure 
The mean systolic and diastolic blood pressures are 129.7 and 85.3 millimeters of 
mercury. There is no statistically significant difference in blood pressure among 
the male and female populations. 
 
Table 5.5 Blood pressure – Male and Female 
(mmHg) Male Female  
BP systolic 128.3±16.1 130.6±15. 0.57 
BP diastolic 85.4±12.5 85.1±11.5 0.94 
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Table 5.6 - Blood Pressure classes of the study subjects according to JNC7 
classes 
BP Number Percentage (%) 
Normal 14 20.8 
Pre Hypertension 35 52.2 
Stage 1 Hypertension 14 20.9 
Stage 2 Hypertension 4 5.9 
 
 
Laboratory values 
 
The table below gives the comprehensive mean data of the laboratory values 
analysed in the study. 
 
 
Table 5.7 Mean Laboratory values – Comprehensive table 
Fasting Blood Sugar (mg/dl) 102 ± 38.49 
Total Cholesterol (mg/dl) 213.76±45.66 
Triglycerides (mg/dl) 128.01±51.37 
LDL (mg/dl) 140.0±42.91 
HDL (mg/dl) 48.41±10.14 
Total Bilurubin (mg/dl) 1±1.02 
AST (IU/L) 32.71±15.34 
ALT (IU/L) 32.74±22.42 
ALP (IU/L) 108.6±53.2 
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Fasting Blood Sugar 
The mean blood sugar value was 102±38.49mg/dl. Among the 67 patients studies, 
19 (28%) had either newly detected impaired fasting glucose levels or diabetes 
mellitus. 
 
Table 5.7 Fasting Blood Sugar values 
Fasting Blood Sugar 
Values  (mg/dl) 
n Percentage (%) 
FBS  <100  
 
48 71.6 
FBS  100-126 
 
10 14.9 
FBS  >126 
 
9 13.4 
 
 
Lipid Profile 
The mean total cholesterol was 213.76±45.66 LDL 140.0±42.91 Triglycerides 
128.01±51.37 and   HDL 48.41±10.14 (all values in mg/dl). The percentage of 
cases falling into each category of lipid levels as per the ATP III norms are given 
below in Table 5.8 
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Table 5.8 - Lipid profile of the study group according to Adult treatment 
panel III classification of LDL, total, and HDL cholesterol 
 
LDL Cholesterol 
(mg/dl) 
No. of values Percentage (%) 
LDL<100 - Optimal  
 
 
12 17.9 
100 to 129 - Near normal 
or above optimal 
 
17 25.4 
130 to 159 -  Borderline 
high 
 
20 29.9 
160 to 189  - High 
 
 
10 14.9 
≥190 -  Very High 
 
 
8 11.9 
 
Total cholesterol (mg/dl) No. of values Percentage (%) 
<200  -  Desirable 29 43.3 
200-239  -  Borderline 
High 
20 29.9 
≥240  -  High 18 26.8 
 
HDL cholesterol (Males) 
(mg/dl) 
No. of values Percentage (%) 
<40 - Low 6 23.1 
≥40 - High 20 76.9 
HDL cholesterol  
(Females ) mg/dl 
No. of values Percentage (%) 
<50  -  Low 21 51.2 
≥50  -  High 20 48.8 
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Liver function tests  
The relevant liver functions results from the study group are given below in the 
tables below. 
Table 5.9 Liver Function tests 
 Number Percentage 
AST > 35 IU/L 20 29.8 
ALT > 35 IU/L 19 28.3 
ALP > 147 IU/L 10 14.9 
 
Table 5.10 Liver fucnction tests compared in alcoholics and non alcoholics 
 Alcohol Related 
Fatty liver 
NAFLD P value 
AST 44.66+33.0 31.54+12.25 0.38 
ALT 57.5+63.5 30.5+12.19 0.34 
ALP 112.5+27.5 108.16+55.21 0.74 
 
 
Metabolic Syndrome 
The number of patients with metabolic syndrome in the study population was 
calculated according to the ATP III guidelines. Among the 67 patients, 19 were 
found to have metabolic syndrome. The data is represented in the figure . 
 
 
 
  
Figure 5.4 Percentage of fatty liver patients with metabolic syndrome 
according the NCEP 
Figure 5.5 – Compilation Bar graph of clinical and laboratory abnormalities
*Since many of the study subjects had more
total from the bar graph will be more than the total study population.
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High Sensitive C – Reactive Protein levels. 
High Sensitive C – Reactive Protein (hsCRP) levels were measured in all the 67 
patients. As indicated earlier only cases with a hsCRP levels <5mg/l only were 
included in study. The mean value of hsCRP level was 2.16±1.11 mg/l. The values 
range was from 0.48 to 4.82   
The statistical characteristics of the serum levels of hsCRP are mentioned in the 
table given below. 
Table 5.11 Statistical characteristics of hsCRP levels 
Mean value 2.1607 
Highest value 4.8200 
Lowest value 0.4800 
95% CI for the mean 1.8905 to 2.4310 
Median 2.0800 
95% CI for the median 1.7306 to 2.3298 
Variance 1.2277 
Standard deviation 1.1080 
Relative standard deviation 0.5128 (51.28%) 
Standard error of the mean 0.1354 
Coefficient of Skewness 0.5931 (P=0.0455) 
Coefficient of Kurtosis -0.5229 (P=0.3087) 
D'Agostino-Pearson test 
for Normal distribution 
accept Normality (P=0.0807) 
 
 
The mean values of hsCRP levels in males and females are outline below. The 
difference is not statistically significant. 
Table 5.12 hsCRP levels comparision in males and females 
55 
 
 Male (n=26) Female (n=41) p-value 
 
hsCRP 
 
2.21±1.14 
 
 
2.18±1.11 
 
0.41 
 
The mean hsCRP values in cases classified to have metabolic syndrome and with 
no metabolic syndrome are and respectively. The p values are less than <0.001 and 
henceforth the difference is highly statistically significant. 
Table 5.13 hsCRP levels compared in fatty liver patients with and without 
metabolic syndrome 
Metabolic Syndrome 
(n=19) 
No Metabolic Syndrome 
(n=48) 
p-value 
 
3.12±0.99 
 
 
1.79±0.92 
 
<0.001 
 
In patients with metabolic syndrome there was a highly significant difference in 
levels of high sensitive CRP levels.On comparing hsCRP levels of alcoholic and 
non alcoholic fatty liver case the following results were obtained.  
Table 5.14 hsCRP levels compared in alcoholic and non alcoholic patients 
 Alcohol related 
Fatty liver disease 
Non alcohol 
related fatty liver 
disease 
p- value 
 
Mean hsCRP 
 
1.96±0.58 
 
2.18±0.92 
 
0.64 
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The mean hsCRP in alcoholics were 1.96±0.58 and NAFLD group were 2.18±0.92 
and there was no statistically significant difference when compared to NAFLD 
group, owing to the small number of alcoholic fatty liver cases in the study. 
A cardiovascular risk classification of low risk (<1.0 mg/L), average risk (1.0 to 
3.0 mg/L), and high risk (>3.0 mg/L) corresponding to hs-CRP in the adult 
population was proposed by the Centers for Disease Control and Prevention and 
the American Heart Association (CDC/AHA). A risk stratification of the study 
group is being done according to the data as shown in the table 5.14. 
Corellation of Different variables with hsCRP. 
The correlation of fatty liver with hsCRP and the various clinical and laboratory 
values were assed using the Pearson product-moment correlation coefficient. The 
following results were obtained as given in table 5.15 
Among the variables, Waist circumference and BMI showed moderate degree of 
correlation. The variable which correlates maximally is waist circumference, a 
correlation factor of 0.61 
Blood pressure showed a weak but, positive correlation 0.3. Among the lipid 
profile, total cholesterol, and Triglycerides and LDL showed weak positive 
correlation, while HDL showed a weak negative correlation. 
The correlation coefficients of liver function tests were not significant or strong. 
Representative scatter diagrams for correlation variables with hsCRP levels on X 
axis are shown below.  
 Table 5.14 Cardiovascular risk stratification of the study population 
according to the hsCRP levels
hsCRP levels 
<1 
1-3 
>3 
Figure 5.7 Pie chart demonstrating Cardiovascular risk stratification of the 
study population according to the hsCRP levels
Table 5.15 – Pearsons cor
CVD risk of the study population according to 
 
Number Percentage (%) 
7 10.4 
46 68.7 
14 20.9 
 
 
relation coefficient – r of hsCRP with
parameters 
 
< 1 - Low 
risk, 
10.40%
1-3 Moderate Risk, 
68.70%
>3 Major Risk, 
20.90%
hsCRP levels
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 various 
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Factor Correlation p-value 
Age -0.04 0.74 
Waist 0.61 <0.001 
Weight 0.51 <0.001 
BMI 0.48 <0.001 
BP(Systolic) 0.32 0.008 
BP(Diastolic) 0.31 0.010 
FBS 0.06 0.620 
TC 0.31 0.010 
TG 0.22 0.073 
HDL -0.26 0.033 
LDL 0.3 0.013 
T.Br -0.06 0.629 
AST -0.01 0.936 
ALT 0.1 0.420 
ALP -0.01 0.936 
 
Figure 5.8 Scatter plot – showing correlation between hsCRP and Waist 
Circumference 
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Figure 5.9Scatter plot – showing correlation between hsCRP and Waist Circumference in 
patients with metabolic syndrome and without metabolic syndrome.
 
Figure 5.10 Scatter plot – showing correlation between hsCRP and BMI
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6.Discussion 
Demographic Profile 
A total of 67 cases with included in the study after applying the exclusion 
criteria. Since patients with any concurrent symptom or illness or chronic illness 
were excluded from the study, a considerably large number of cases diagnosed 
with fatty liver were ruled out of the study. 12 patients, who would have qualified 
otherwise, had high hsCRP levels, i.e. more than 5 mg/l. A level more that 5mg/dl 
is considered to be representative of infection, inflammation surgery or traumatic 
origin and not of cardiovascular risk. 61 So these cases were excluded from the 
study. 
In this study the predominant population was female - 61%. The mean age 
of the participants was 48 ± 12.5 years. Majority of the patients (40) belonged to 
31-50 age group. Almost all studies from all over India reports that the proportion 
of males in more , if not equal. Amarapurkar  et al in 2000 reportes a male to 
female ratio of 2:1, Bhat etal in 2006 reported a ration of 3:1 . 62,63 This of course 
depends on the population demographics of people attending the Master health 
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checkup clinic. But considering the fact that 6 male patients of alcoholic fatty liver 
disease is also included, this female predominance may be significant. 
 
Anthropometric characteristics 
Among the measured anthropometric characteristics, the mean BMI was 
26.7±4.9. Most of the patients fell in to the class of Normal BMI n= 26 (39%) 
followed by Overweight- n=21 (31 %.). Many Indian studies give similar 
observation. A study from coastal eastern India has shown that only about 46% of 
NAFLD patients were either overweight or obese (meaning that more than 50% 
were having a normal BMI as per the WHO criteria). On the contrary, only about 
22% of the patients in the studies by Uchil et al. and Duseja et al. had a normal 
BMI. In contrast, abnormal BMI has been documented in 40%-100% of NAFLD 
patients in the West. 14,15,18 So it is evident that, according to BMI values, 
comparatively less patients qualify to have obesity when compared to western data. 
BMI classes do not take race and population characteristics into 
consideration. Since the Indians, especially South Indian population is known to 
have more visceral fat as compared to others BMI measurement may underestimate 
obesity and associated risks. 
Waist Circumference seems more reliable in this regard. 65% of the males 
and 46% of females had a waist circumference above the cutoff values proposed by 
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the NCEP – ATP recommendations. Duseja et al reported that 72% of the male and 
93% of the female population had a waist circumference that was more than the 
proposed cutoff (Waist circumference >90 cm in males and more than 80 cm in 
females). Some other Indian studies show lesser prevalence though, like Amarkpur 
etal observing high WC in 57% of the patients. 62, 63 But universally the waist 
circumference appears to be above normal in a good number of cases diagnosed 
with fatty liver disease. 
Clinical Features and Labortaty measurements. 
A total of 18 (27%) new hypertensive and 35 pre-hypertensive patients were 
discovered during the study.  Ramachandran et al reported an age-adjusted 
hypertension in Chennai (South India) as 21.8% in a sample of 532 males and 421 
females aged >40 years. This study included general population, not fatty liver 
patients. Essential hypertension is associated with the metabolic syndrome, insulin 
resistance and the development of fatty liver. M J Brookes and B T Cooper in 
Journal of Human Hypertension, states that it is important to consider the diagnosis 
of fatty liver disease in hypertensive patients, to measure the liver function tests at 
diagnosis and not to ignore minor elevations of serum aminotransferases. 
Considering the fact that these patients were asymptomatic, and if not for the 
health screening their blood pressure would not have come to the light, screening 
for hypertension should be strongly recommended in fatty liver patients. 
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The study showed that 10 0ut of the 67 (15%) of asymptomatic patients presenting 
with fatty liver had impaired fasting blood sugars and 9 had (13.4%) had diabetes 
mellitus. This is to be considered while keeping the the fact that the reported 
prevalence of diabetes among the general population in Chennai is 13.5%, in a 
study Mohan etal. 64 
Regarding diabetes mellitus other Indian studies have reported a prevalence 
of 12-25% .A recent study on the prevalence of NAFLD among Italian diabetic 
population reported a figure of 69.5%. In a study among healthy Japanese adults, 
the prevalence of NAFLD increased from 27% with normal fasting glucose to 43% 
in those with impaired fasting glucose and to 62% in subjects with newly 
diagnosed diabetes. In others studies from Asia pacific region, the prevalence of 
NAFLD among diabetic subjects was 54.5%, which is significantly higher than 
those found among subjects with pre-diabetes (IGT or IFG) (33%), which in turn is 
higher than those with normal glucose tolerance (22.5%). 65 66 
Among the 67 patients only 6 had clinically appreciable heaptomegaly. The 
incidence of hepatomegaly in different studies range from (Saudi series (2003) - 
(88%)  Virginia series (1996) - (22%) Lal et al (1991) - (40%). But in our study it 
was only 9%. 67 
Among the liver function tests, the mean transaminase levels AST and ALT 
were 32.7±15.3 and 32.7±22.42 respectively . A clinically significant relationship 
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could not be established regarding the liver function test values obtained in the 
current study. Around 30% had eleveated transaminases in our study, considering 
cut off values for AST and ALT as 35IU/L. There is poor correlation between 
biochemistry, ultrasonography and histology,  and the entire histological spectrum 
of NAFLD can be seen in individuals with normal transaminase values according 
to Mofrad et al, 2003. 68 Some studies have mentioned that Liver enzyme levels in 
NAFLD patients fluctuate, normal values being present in up to 78% of patients at 
any one time. When levels are elevated, the increase is mild and often restricted to 
one or both of alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST). The AST:ALT ratio is usually less than 1, although it may reverse in the 
presence of cirrhosis. 69 The AST:ALT ratio in the study group was 0.9 Many 
studies have reported that Alanine aminotransferase level showed the strongest 
association with fatty liver, a finding that is not surprising because this is a 
commonly used method to detect NAFLD in the general population.70 But such an 
association could not be found out in our study. Amino-transferase levels are 
commonly used in clinical practice to estimate liver inflammation, but the use of 
ALT level as a reliable indicator of the severity in NAFLD is controversial as 
aminotransferase levels may vary from normal levels in more than two-thirds of 
NASH patients at any given time. 68, 69, 70 We found that among subjects with fatty 
liver at ultrasound, those with normal and abnormal ALT levels were very similar, 
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providing indirect evidence that ALT is not sorting out different conditions or 
stages of the disease. The mean alkaline phosphatase levels were 108.6±53.2.  
There was plenty of lipid abnormalities in the study population. 26% had 
total cholesterol more than 240 mg/dl. 8 out of 67 (12%) had a LDL value greater 
than 190 mg/dl. A total of 38 among the 67 had LDL values greater than 130 
mg/dl. 27 had abnormal (low) HDL values. The Framingham Heart study found 
higher triglycerides, and lower high-density lipoprotein (HDL) and adiponectin 
levels in patients with fatty liver. Subsequent research from all over the world 
confirmed it.71 
 
Alcohol Related Fatty Liver 
Alcohol consumption was enquired in the history and a total of 6 patients 
gave the history of significant alcohol consumption. All the 6 were males, and in 
good health. There were no clinical features of chronic liver diseases and not much 
dearrangement of liver functions except for one patient who had slightly elevated 
bilurubin and transaminase level. The patients with alcohol related fatty liver 
disease tend to be of normal weight and BMI and without much of other 
anomalies. However the number of patients with alcohol related (n=6) was not 
large enough to make any statistically significant conclusions.  
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Metabolic syndrome  
Metabolic syndrome was detected in 19, ie 28% of the patients with fatty 
liver. If only patients with NAFLD are taken into consideration then it comes to 31 
%. 33 The relationship between NAFLD and metabolic syndrome is becoming 
increasingly recognized. Lizardi-Cervera J et al from Spain reports that of 22 % of 
adults with NAFLD has metabolic syndrome.  Various studies  by Hellen Kang 
etal, Sameul et al and others has found out that prevalence of metabolic syndrome 
as 18-40%. Atleast one component of metabolic syndrome may be present in 90% 
of the NAFLD population. But it is still unclear whether NAFLD can be called as 
the hepatic component of metabolic syndrome, considering only less than one by 
third among the patients qualified for metabolic syndrome criteria. 
 
hsCRP levels 
The mean hsCRP levels in this study were 2.61±1.11mg/L. Sparse data is 
available regarding the normal levels of hsCRP levels in general population. 
Studies do indicate that a CRP level more than 1 mg/L is indicative moderate CAD 
risk. So a mean 2.61±1.11mg/L puts the study group as whole in risk for coronary 
artery disease. The levels of increased serum CRP correlates with the presence of 
traditional cardiovascular risk factors and may reflect contributions of these risk 
factors to vascular inflammation. So it is difficult to make a conclusion regarding 
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whether the fatty liver is an independent variable determining levels CRP in this 
study. A 2000 meta-analysis of 11 of the early population-based studies found a 
two-fold increase in relative risk (95% CI 1.6-2.5) for major coronary events 
between the upper and lower titers of hs-CRP, independent of clinical risk 
assessment or lipid profile. hsCRP being described as an independent risk factor 
for coronary artery disease, there could possibly be a common factor that is 
involved in CAD and fatty liver. Ndumele C etal 74 has found out hepatic steatosis, 
obesity, and the metabolic syndrome are independently and additively associated 
with increased systemic inflammation 
According to AHA, low, intermediate, and high risk values were defined as <1, 1 
to 3, and >3 mg/L. In this study 46 patients (68.7%) were found to have hsCRP 
values more than 1mg/L, while 14 (20.9%) had hsCRP values more than 3mg/L.  
Only 7 among the study group had CRP values less than 1mg/L. 
Another noticeable finding is the statistically significant high levels of hsCRP 
found in patients with metabolic syndrome. This is in line with other studies which 
show high levels of hsCRP in patients with metabolic syndrome. A Spanish study 
by Rodríguez-Leal etal found out that even though the hsCRP levels are high, use 
of hsCRP for the identification of hepatic inflammatory response in patients with 
Metabolic syndrome with NAFLD is limited because of its low sensibility and 
specificity observed on identifying different degrees of hepatic inflammation. 
72There is a moderate to strong positive correlation (r = 0.61) between the serum 
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levels of hsCRP and waist circumference. BMI and body weight also showed 
positive correlation, but not as strong as waist circumference. Waist circumference 
seems to be the best anthropometric measurement suited for our population for 
obesity risk classification. Another advantage is that it is easy to measure and the 
only equipment needed is measuring tape. Contrary to this, measuring BMI needs a 
weighing machine and height scale. And the calculation of the data (weight/height 
2) also needs to be done.  
The findings in this study are in line with others studies done on hsCRP and fatty 
liver. CRP levels and similar findings were noted in the ARIC study, which 
assessed the association of 19 novel risk markers including serum CRP with 
incident CHD in nearly 16, 000 adults followed for up to 15 years . Recently, a 
study reported increased serum levels of hs-CRP in cases of histologically 
confirmed NASH compared with simple non-progressive steatosis. A study by 
Zhou etal from China WD finds close correlation with hsCRP and insulin 
resistance. A study in Chilean hipsanic population finds higher hsCRP levels in 
patients with steatohepatitis. 73,74 James P. Luyendyk, Grace L. Guo s in his 
editorial on comments that the association between fatty liver disease and hs-CRP 
levels strongly suggests that assessing, preventing, and treating nonalcoholic fatty 
liver disease development is one potential strategy to reduce systemic 
inflammation and the risk of adverse cardiovascular outcomes in patients with 
metabolic syndrome. 75 Our results indicate that with further studies hs-CRP may 
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be considered as another non-invasive marker of NAFLD, adding a new tool to the 
repertoire of the primary care physicians and  hepatologists attempting to establish 
a diagnosis of NAFLD. 
 
 
                              7.Limitations of the study 
1. The study population is derived from people who are attending health 
screening. They cannot be considered as representative of general 
population. 
2. Due to limitations in logistics and technical capability, certain investigations 
like insulin levels, tranferrin saturation, serum iron levels, ferritin levels, and 
ceruloplasmin levels were not measured. Radiological fatty liver was not 
confirmed by liver biopsy, due to both technical limitations and relectance 
from the patients part to undergo an invasive procedure 
3. The number of alcohol related fatty liver cases were very less, so not much 
statistically relevant data could not be obtained from that group. 
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8.Conclusions 
1. Asymptomatic population diagnosed with fatty liver has a significant 
proportion of clinical and metabolic abnormalities. 
2. All good number of patients had Obesity, Hypertension Diabetes, 
Prediabetes, and Dyslipidemias – all of these previously undetected 
abnormalities were newly diagnosed 
3. Even though generalised malaise, right hypochondrial pain, hepatomegaly 
are considered to be prominent symptoms and signs of  NAFLD, a good 
portion of fatty liver disease patients may be still living in the society 
without being detected, but harboring potential cardiovascular risk factors.  
4. Asymptomatic patients need detailed evaluation and interventions since they 
have high prevalence of atherogenic and cardiovascular risk factors. 
5. Alcoholics formed only a minor portion (8.9%) of the fatty liver group. That 
makes the rest 61 (91.1%) cases of Non Alcoholic Fatty Liver Disease. 
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6. Waist circumference seems to be the best parameter to quantify obesity and 
metabolic risk. 
7. The AST and ALT levels, which are often used to diagnose and categories 
NALF and NASH were found to be having no significant associations with 
other variables in this study. This reimburses the fact that AST and ALT 
levels can vary even during course of the disease and it is not a sensitive or 
specific modality to diagnose NAFLD. It has to be supplemented by imaging 
or biopsy. 
8. Not all NAFLD patients qualified for metabolic syndrome as per NCEP-
ATP III criteria. Among them 19 patients qualified were diagnosed with 
metabolic syndrome.  
9. Using the AHA classification CRP for coronary artery risk, 93% of the study 
populations are at risk of development of atherosclerotic, coronary artery 
disease.  
10. CRP has a moderate to strong positive correlation to the waist 
circumference, BMI and weight in the study group ie CRP values tend to 
increase with obesity. 
11. CRP levels are significantly high in patients with Fatty liver disease 
associated with metabolic syndrome. 
12. CRP may be useful in risk stratification of Fatty liver disease. A long term 
prospective study will be needed to validate this.  
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13. Further research into CRP and other pro-inflammatory markers in fatty liver 
disease may provide vital information regarding the pathogenesis of fatty 
liver disease and has the potential of opening up new avenues for targeted 
treatment. 
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ABBREVIATIONS 
 
ALP - Alkaline phosphatase 
ALT - Alanine Aminotransferase 
AST - Aspartate Aminotransferase 
CRP - C Reactive Protein 
HDL - High density lipoprotein 
hsCRP - High sensitivity C reactive protein 
LDL - Low density lipoprotein 
MS - Metabolic Syndrome 
T.B - Total Bilurubin 
TC - Total Cholestrol 
TG – Triglycerides 
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Master Chart – Page 1 
N OP No Ag S A WC Wt Ht BMI C L BPS BPD FBS TC TG HD LDL TB AS AL AP B C CRP 
1 4259 55 1 0 89 78 1.66 28.3 0 3 130 96 82 236 139 52 156 0.8 23 17 146 0 0 3.62 
2 4559 36 1 0 96 77 1.67 27.6 0 0 120 70 90 210 112 60 128 0.7 26 30 40 0 0 4.5 
3 4322 50 1 0 73 60 1.52 25.9 0 0 120 80 283 183 60 58 113 1 30 29 230 0 0 2.56 
4 3211 43 0 0 74 70 1.73 23.3 0 0 128 70 90 176 70 56 106 0.8 25 18 76 0 0 1.81 
5 4915 52 0 0 86 72 1.62 27.4 0 0 130 90 74 196 143 32 135 0.6 34 22 82 0 0 1.08 
6 23440 35 0 1 88 76 1.71 25.9 0 4 126 80 99 222 78 50 156 2 110 186 160 0 0 1.08 
7 4515 30 1 0 79 57 1.6 22.2 0 0 118 76 92 212 126 36 151 0.8 45 38 77 0 0 1.08 
8 4639 39 1 0 104 82 1.59 32.4 0 0 160 110 112 330 212 43 245 1 56 67 90 0 0 4.08 
9 4526 42 1 0 82 65 1.53 27.7 0 0 140 90 78 246 130 40 180 0.8 34 23 101 0 0 1.73 
10 23126 44 0 0 70 60 1.59 23.7 0 0 120 80 89 202 139 59 115 0.8 23 22 38 0 0 2.45 
11 3400 55 0 0 76 65 1.59 25.7 0 0 128 80 78 283 174 30 218 0.8 33 31 90 0 0 1.06 
12 4026 46 0 0 80 70 1.7 24.2 0 0 120 80 70 212 102 50 138 1 22 12 68 0 0 2.86 
13 23455 32 1 0 72 68 1.63 25.5 0 0 100 70 55 310 286 44 209 0.8 44 52 75 0 0 1.51 
14 994 70 0 1 68 48 1.65 17.6 0 0 100 70 186 210 127 45 140 0.8 35 44 112 0 0 2.1 
15 2119 65 1 0 72 60 1.55 24.9 0 0 130 80 76 246 155 77 138 1.8 43 55 134 0 0 1.08 
16 4470 76 0 0 78 70 1.75 22.8 0 0 180 120 76 150 76 54 81 0.7 33 29 108 0 0 3.22 
17 4444 56 1 0 96 80 1.59 31.6 0 0 140 90 140 190 110 47 121 1 45 54 356 0 0 2.45 
18 2401 72 1 0 68 58 1.62 22.1 0 0 122 80 98 210 100 48 142 0.7 18 16 79 0 0 1.28 
19 4217 78 0 0 80 55 1.57 22.3 0 0 130 90 112 183 112 50 111 0.6 24 19 89 0 0 2.24 
20 4510 45 1 0 82 66 1.46 30.9 0 0 140 90 110 165 102 50 95 1 40 22 126 0 0 1.1 
21 3367 59 1 0 75 48 1.69 16.8 0 0 110 70 79 156 78 55 85 0.7 22 24 112 0 0 1.82 
22 3245 49 1 0 84 61 1.72 20.6 0 0 176 108 94 228 148 41 157 1.2 18 23 87 0 0 2.12 
23 234098 40 0 0 94 70 1.72 23.6 0 0 130 90 110 256 170 36 186 0.7 45 55 108 0 0 4.82 
24 342 47 0 1 76 69 1.58 27.6 0 0 130 80 96 186 66 53 120 2 22 26 113 0 0 2.33 
25 4683 72 1 0 75 52 1.53 22.2 0 0 140 90 78 189 110 50 117 0.7 18 22 107 0 0 2.3 
26 4196 41 1 0 89 79 1.62 30.1 0 0 150 95 106 242 160 32 178 0.7 28 31 61 0 0 2.06 
27 223601 64 1 0 98 70 1.5 31.1 0 0 136 90 116 202 136 45 130 0.8 56 47 118 0 0 3.08 
28 2383 49 1 0 84 73 1.57 29.6 0 0 130 90 98 156 83 67 72 7 33 38 82 0 0 2.12 
29 3456 39 1 0 104 67 1.44 32.3 0 3 126 80 85 212 136 49 136 0.6 36 34 107 0 0 2.12 
30 2467 43 0 1 77 79 1.68 27.9 0 2 124 84 83 190 68 65 111 0.8 36 40 74 0 0 1.45 
31 2349 67 1 0 66 67 1.7 23.1 0 0 140 90 140 210 110 43 145 1.4 32 28 134 0 0 1.05 
32 12472 42 1 0 78 59 1.59 23.3 0 0 150 100 70 153 70 50 89 0.8 23 22 98 0 0 1.1 
33 4119 60 1 0 89 76 1.64 28.2 0 0 110 70 88 210 130 32 152 0.8 21 22 60 0 0 1.71 
34 660 62 0 0 112 106 1.61 40.8 0 0 140 90 92 260 208 42 176 0.8 32 28 58 0 0 2.85 
35 4433 39 0 0 108 94 1.71 32.1 0 0 126 80 90 225 186 34 154 0.8 35 28 136 0 0 4.08 
36 4474 32 0 0 90 74 1.58 29.6 0 2 110 80 91 226 140 35 163 0.7 23 30 212 0 0 1.02 
37 4911 48 1 0 76 59 1.58 23.6 0 0 150 100 98 270 310 44 164 0.9 77 43 106 0 0 1.08 
38 4612 38 1 0 84 72 1.6 28.1 0 0 119 70 110 328 56 70 247 0.7 34 56 93 0 0 2.12 
39 5033 29 1 0 94 82 1.75 26.7 0 0 130 90 94 240 163 40 167 0.6 23 25 192 0 0 2.04 
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Master Chart – Page 2 
N OP No. Ag S A WC Wt Ht BMI C L BPS BPD FBS TC TG HD LDL TB AS AL AP B C CRP 
40 4135 45 0 0 84 70 1.5 31.1 0 0 120 80 86 160 76 51 94 1.2 21 18 83 0 0 2.85 
41 4549 58 0 0 74 58 1.63 21.8 0 0 110 70 130 180 110 58 100 1 28 34 40 0 0 0.48 
42 5042 40 1 1 112 98 1.6 38.2 0 3 130 90 79 280 189 33 209 1 22 26 108 0 0 3.72 
43 8832 55 0 1 94 64 1.7 22.1 0 0 110 70 89 182 100 56 106 1.9 43 23 108 0 0 1.06 
44 3444 66 1 0 72 68 1.69 23.8 0 0 126 80 56 170 86 58 95 0.8 21 20 50 0 0 2.42 
45 2135 39 1 0 76 64 1.62 24.3 0 0 110 70 89 160 86 59 86 1 12 22 194 0 0 1.22 
46 23319 37 0 0 112 98 1.76 31.6 0 0 136 90 86 326 173 46 245 1.4 50 52 128 0 0 3.89 
47 4664 51 0 0 96 77 1.58 30.8 0 0 150 110 225 216 180 48 132 0.8 53 32 88 0 0 2.83 
48 4090 31 1 0 84 80 1.7 27.6 0 0 120 89 90 210 132 48 136 0.8 18 16 178 0 0 0.86 
49 4357 34 1 0 80 71 1.66 25.7 0 0 126 76 84 220 140 54 138 0.8 45 46 184 0 0 1.18 
50 113445 43 1 0 76 48 1.47 22.2 0 0 110 70 88 172 69 40 118 0.7 18 22 89 0 0 0.86 
51 4168 22 0 0 92 68 1.53 29.0 0 0 112 70 89 210 132 45 139 0.8 26 22 63 0 0 2.4 
52 3402 58 1 0 96 76 1.53 32.4 0 0 140 90 96 226 163 60 133 1 42 40 85 0 0 3.21 
53 601 42 1 0 70 44 1.43 21.5 0 0 110 70 81 160 141 50 82 1 24 33 122 0 0 1.83 
54 54567 51 1 0 80 69 1.68 24.4 0 0 126 80 90 181 110 56 103 0.8 50 44 80 0 0 2.96 
55 2001 44 0 0 86 74 1.75 24.1 0 0 130 90 94 240 140 36 176 0.7 25 21 110 0 0 1.12 
56 31076 56 1 0 98 84 1.64 31.2 0 0 140 90 88 308 224 34 229 0.8 25 22 44 0 0 3.86 
57 4777 63 1 0 76 47 1.46 22.0 0 0 150 110 225 194 80 47 131 1 32 27 90 0 0 2.08 
58 4132 35 1 0 112 102 1.58 40.8 0 0 130 90 90 248 160 36 180 0.6 24 22 100 0 0 4.59 
59 3210 55 0 0 80 77 1.61 29.7 0 0 126 86 72 177 88 55 104 1 19 22 72 0 0 0.68 
60 262335 43 0 0 82 68 1.68 24.0 0 0 160 110 129 187 105 49 117 0.4 33 38 67 0 0 2.98 
61 4848 40 1 0 68 48 1.42 23.8 0 0 120 80 89 158 70 58 86 0.7 23 20 126 0 0 1.88 
62 4198 39 1 0 76 69 1.65 25.3 0 0 136 82 101 170 70 60 96 0.7 23 30 80 0 0 3.6 
63 2112 50 0 0 80 62 1.56 25.4 0 0 130 90 87 180 110 43 115 0.7 18 20 213 0 0 0.65 
64 4465 37 1 0 69 55 1.54 23.1 0 0 128 80 120 195 160 38 125 0.9 43 26 98 0 0 0.8 
65 4656 48 1 0 108 78 1.5 34.6 0 0 156 100 106 250 170 56 160 0.9 35 36 182 0 0 3.91 
66 4657 44 0 0 92 84 1.64 31.2 0 0 130 90 167 280 170 45 201 0.9 40 34 55 0 0 1.83 
67 4630 49 1 0 70 48 1.65 17.6 0 0 110 70 98 172 62 61 99 0.6 22 18 101 0 0 0.86 
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Key to master chart 
N – Serial Number 
OP No.- Op number 
Ag – Age 
S – Sex (Male 0, Female 1) 
A – Alcohol Intake ( 0 – No, 1 – yes) 
WC – Waist Circumference 
Ht – Height 
Wt- Weight 
BMI – Body Mass Index 
C – Significant Clinical Features 
L – Liver size ( in cms) 
BPS – Blood pressure , Systolic 
BPD – Blood pressure, Diastolic 
FBS – Fasting Blood Sugar 
TC – Total Cholesterol 
TG – Triglycerides 
HD – High density lipoproteins 
LDL – Low density lipoproteins 
TB – Total bilurubin 
AS – Aspartate aminotransferase 
AL- Alanine aminotransferase 
AP – Alkaline phosphatase 
B – HbSAg 
C – Anti HCV 
CRP – High Sensitive C reactive protein 
 
